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Abstract: Speckle-type POZ (pox virus and zinc finger protein) protein (SPOP) is the most commonly
mutated gene in prostate cancer (PCa). Recent evidence reports a role of SPOP in DNA damage
response (DDR), indicating a possible impact of SPOP deregulation on PCa radiosensitivity. This study
aimed to define the role of SPOP deregulation (by gene mutation or knockdown) as a radiosensitizing
factor in PCa preclinical models. To express WT or mutant (Y87N, K129E and F133V) SPOP, DU145
and PC-3 cells were transfected with pMCV6 vectors. Sensitivity profiles were assessed using
clonogenic assay and immunofluorescent staining of γH2AX and RAD51 foci. SCID xenografts were
treated with 5 Gy single dose irradiation using an image-guided small animal irradiator. siRNA
and miRNA mimics were used to silence SPOP or express the SPOP negative regulator miR-145,
respectively. SPOP deregulation, by either gene mutation or knockdown, consistently enhanced
the radiation response of PCa models by impairing DDR, as indicated by transcriptome analysis
and functionally confirmed by decreased RAD51 foci. SPOP silencing also resulted in a significant
downregulation of RAD51 and CHK1 expression, consistent with the impairment of homologous
recombination. Our results indicate that SPOP deregulation plays a radiosensitizing role in PCa by
impairing DDR via downregulation of RAD51 and CHK1.
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1. Introduction
Speckle-type POZ (pox virus and zinc finger protein) protein (SPOP) is an adaptor for
the E3 ubiquitin ligase Cullin 3 that selectively binds to and targets substrates for ubiquitination
and proteasome degradation [1]. Genome-wide next generation sequencing studies have revealed
that SPOP is frequently mutated in a number of cancer types such as prostate and endometrial [2,3],
thus suggesting SPOP as a putative tumor suppressor. Counterintuitively, SPOP is overexpressed
in other cancer types such as clear cell renal cell carcinoma, where it acts as a tumorigenic hub [4],
indicating that the role of SPOP in cancer is likely tumor type dependent.
SPOP binds to its substrates via the N-terminal meprin and traf homology (MATH) domain [1],
while it interacts with Cullin 3 through the bric-a-brac/tramtrack/broad complex (BTB) domain at
the C-terminus [1]. SPOP mutations observed in human cancers are clustered in the MATH domain [2,3],
suggesting that they may promote cancer via altering the stability of its substrates (Figure 1). SPOP
mutations occur early in the natural history of prostate cancer (PCa) and are present in about 10% of
both clinically localized and metastatic disease, thus representing the most common non-synonymous
mutations in PCa [2,5,6]. SPOP mutations define a distinct molecular class of PCa, with a high frequency
of characteristic genomic rearrangements, but they are mutually exclusive with rearrangement between
TMPRSS2 and the ETS family of transcription factors (mainly TMPRSS2:ERG) [2,7].
Figure 1. Illustration of SPOP domains and localization of prostate cancer-specific mutations.
A number of highly relevant substrates have been reported as deregulated by mutant SPOP in
PCa cells, including the androgen receptor (AR) and its co-activators steroid-receptor co-activator-3
(SRC-3) and tripartite motif containing 24 (TRIM24) [8–12]. However, the relevance of these findings
for prostate tumorigenesis is still unclear. Recent evidence obtained on a transgenic mouse with
prostate-specific conditional expression of SPOP-F133V—the most frequent mutation observed in
PCa—indicates that SPOP mutation alone is insufficient to drive tumorigenesis in the mouse prostate.
Conversely, in the setting of phosphatase and tensin homolog (PTEN) loss, conditional expression of
mutant SPOP in the prostate induced the appearance of high-grade prostatic intraepithelial neoplasia
(PTEN heterozygous background) and invasive poorly differentiated carcinoma (PTEN homozygous
background), suggesting that mutant SPOP is able to cooperate with PTEN to drive carcinogenesis [13].
In addition, using mouse prostate organoids, it was shown that, in PTEN WT background, SPOP-F133V
not only promotes AR signaling but also induces SRC-3-mediated activation of PI3K/mTOR signaling,
thus effectively uncoupling the normal negative feedback between these two pathways [13].
Still limited experimental data indicate a possible impact of mutant SPOP on treatment response.
Results obtained in primary prostate cells from conditional SPOP-F133V transgenic mice, as well
as in human normal prostate and PCa cell lines ectopically expressing SPOP-WT or SPOP-F133V,
suggest that SPOP participates in the DNA damage response (DDR) and that SPOP mutation impairs
homologous recombination (HR) [7], which is the main repair pathway of DNA double strand breaks
(DSB). Consistently, it has been reported that SPOP loss impairs RAD51 foci formation in response to
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radiation-induced DNA DSBs [14]. Moreover, SPOP knockdown was found to lead to spontaneous
replication stress and impaired recovery from replication fork stalling, due to the transcriptional
suppression of RAD51 and CHK1, two main factors involved in HR [14]. In line with these findings,
SPOP knockdown in human cervical carcinoma [15] and lung adenocarcinoma [16] cells resulted in
impaired DDR and hypersensitivity to ionizing radiation.
Radiotherapy, alone or in association with androgen deprivation, is one of the main treatment
options for organ-confined PCa [17]. Relevant advancements in treatment planning and delivery
have significantly improved local tumor control. However, a considerable proportion of patients still
experience recurrence due to resistance development [18]. The onset of radioresistance is a complex
and still poorly understood phenomenon that hinges on the deregulation of a plethora of signaling
pathways as a result of several genetic and epigenetic abnormalities [19].
In the present study, we aimed to define the role of cancer-specific SPOP mutations as
radiosensitizing factors in preclinical models of PCa. The obtained findings were then confirmed in PCa
cells in which SPOP expression was downregulated by siRNA or through the reconstitution of miR-145,
which is a physiological negative regulator of the gene [20]. Results from the study, which represents
the first attempt to directly compare the radiosensitizing effect of SPOP deregulation accomplished
through different approaches, could contribute to tailoring therapy of individual PCa patients by
delivering a genomic-adjusted radiation dose, instead of a uniform dose (i.e., one-size-fits-all) and to
highlight the possibility of developing novel strategies of radiosensitization based on SPOP targeting.
2. Results
2.1. SPOP Mutation Sensitizes PCa Models to Ionizing Radiation
To investigate the potential of PCa-specific SPOP mutations as radiosensitizing factors in PCa,
we transfected DU145 and PC-3 cell lines with pMCV6 expression vectors encoding for WT or mutant
(Y87N, K129E and F133V) SPOP and assessed the effect on cell response to 2–8 Gy γ irradiation via
clonogenic assay. Transfection with WT SPOP did not modify the plating efficiency of parental cells,
while a reduced plating efficiency was consistently observed in cells transfected with mutant SPOP
(Supplementary Table S1). Interestingly, although the overexpression of WT SPOP did not affect
the radiosensitivity profile of either cell line, mutant SPOP ectopic expression enhanced radiosensitivity
of both cell lines, independently of the type of mutation, as revealed by the reduction in their clonogenic
cell survival compared to WT SPOP, which was statistically significant along the whole dose range
(Figure 2A). Remarkably, the dose enhancement ratio (DER), here defined as the ratio of the radiation
dose required to obtain a surviving fraction (SF) of 0.1 in WT SPOP cells to that required to obtain
the same SF in mutant SPOP cells, was consistent for the different SPOP mutations (ranging from 1.31
to 1.43 in DU145 cells and from 1.22 to 1.31 in PC-3 cells), meaning that the radiosensitizing effect of
mutant SPOP was independent of the type of mutation (Figure 2A).
To confirm the radiosensitizing effect observed in vitro also in an in vivo setting, SCID mice were
subcutaneously transplanted with DU145 cells stably expressing F133V SPOP—the most frequent
PCa-specific SPOP mutation [2]—to generate xenografts. Mice were exposed to 5 Gy single dose
irradiation when tumors reached a volume of ~300 mm3 (24 days after cell inoculum). Interestingly,
the ectopic expression of F133V SPOP increased the effect of radiation also in vivo, as shown by
the statistically significant reduction in tumor growth upon irradiation compared to WT SPOP
xenografts (Figure 2B).
Overall, these findings indicate that mutant SPOP is able to enhance PCa cell response to ionizing
radiation both in vitro and in vivo.
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Figure 2. SPOP mutations sensitize PCa cell and animal models to ionizing radiation. (A) Clonogenic
cell survival curves of DU145 and PC-3 cells ectopically expressing WT or mutant (Y87N, K129E,
F133V) SPOP and exposed to increasing doses of irradiation (2, 4, 6 and 8 Gy). The surviving fraction
is reported as mean ± SD values from three independent experiments. The level of significance was
represented as * p < 0.05, ** p < 0.01, Student’s t-test. The dose enhancement ratio (DER) was calculated
as the dose (Gy) for the radiation plus mutant SPOP divided by the dose (Gy) for radiation plus WT
SPOP at a surviving fraction of 0.1. (B) DU145 cells stably expressing WT or F133V SPOP (1 × 107) were
subcutaneously implanted into SCID mice. When tumors reached ~300 mm3, mice were randomly
assigned to four groups (8 mice/group) and treated with 5 Gy single dose irradiation locally delivered
to the tumor. Tumor growth volume (mm3) was measured with a Vernier caliper on indicated days
after cell injection.
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2.2. SPOP Mutation Affects PCa Cell Radiation Response by Impairing Homologous Recombination
To get insight into the molecular mechanisms underpinning the radiosensitizing effect of mutant
SPOP, a differential gene expression analysis comparing F133V SPOP with WT SPOP DU145 cells was
carried out. Since among 12,457 assessed genes only 210 had a significant change (false discovery
rate, FDR < 0.05) in their expression profile, we decided to evaluate modulation in pathways instead
of single genes. To this purpose, we performed a pre-ranked gene set enrichment analysis (GSEA)
on the Hallmark collection, which summarizes the main well-defined biological activities in a cell.
By ranking gene expression according to the t-value obtained in the differential expression analysis,
we obtained a list of significantly modulated gene sets, where the normalized enrichment score
(NES) represents the magnitude of enrichment in F133V SPOP cells (Figure 3A). Notably, among
the pathways enriched in F133V SPOP cells, we found an “androgen response” pathway, supporting
the previously reported contribution of the mutant gene in up-regulating androgen receptor (AR)
activity [13] (Figure 3B).
Figure 3. F133V SPOP mutation deregulates DNA repair-related pathways. (A) Volcano plot of Hallmark
collection gene sets from Molecular Signature database (MsigDB); normalized enrichment score (NES)
and false discovery rate (FDR, 0.05 threshold to assess significance) were plotted. Dots highlight
the enriched gene sets in F133V SPOP mutated (red) and in WT (blue) cells. (B) Gene set enrichment
analysis (GSEA) enrichment plot of “androgen response” and “DNA repair” in the comparison between
F133V SPOP and WT DU145 cells.
Consistent with the SPOP role in determining cell response to radiation by influencing DNA
damage repair, we found that the “DNA repair” pathway was prevalently enriched in WT cells, showing
a downregulation upon SPOP mutation (Figure 3B). Other pathways related to DNA damaging stimuli,
such as “UV response”, were differentially enriched between SPOP mutant and WT cells. Specifically,
“UV response down (dn)” emerged as a significant enriched gene set in F133V SPOP cells, and,
consistently, the inverse pathway “UV response up” showed a coherent trend in WT SPOP cells.
To functionally characterize the role of mutant SPOP in DNA damage and repair, we evaluated
the presence of nuclear γH2AX foci, a specific marker of DNA double strand breaks (DSBs), in F133V
SPOP compared to WT SPOP cells. Immunofluorescence staining showed that radiation treatment
induced extensive and comparable DNA damage in both WT and F133V SPOP expressing cells,
as indicated by a similar number of γH2AX foci at 1 h upon irradiation (Figure 4A), confirming that
the presence of mutant SPOP does not affect the induction and recognition of DNA damage upon
treatment. Conversely, F133V SPOP cells showed a markedly reduced ability to remove DNA DSBs
compared to WT SPOP cells, as indicated but the significantly higher number of γH2AX foci still
present at 8 h following irradiation (Figure 4A).
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Figure 4. F133V SPOP impairs cell ability to recover from radiation-induced DNA damage.
(A) (Left panel) Representative immunofluorescence microphotographs of nuclear γH2AX foci in DU145
WT or F133V SPOP cells at 0, 1 and 8 h upon 6 Gy irradiation. (Right panel) Quantification of γH2AX
foci in WT or F133V SPOP DU145 cells, expressed as mean percentage of cells containing >10 γH2AX
foci at 0, 1 and 8 h upon irradiation. Data are reported as mean ± SD values. The level of significance
was represented as *** p < 0.001, Student’s t-test. (B) (Left panel) Representative immunofluorescence
microphotographs of RAD51 nuclear foci in DU145 WT or F133V SPOP cells at 0 and 8 h upon irradiation
(6 Gy). (Right panel) Quantification of RAD51 foci expressed as mean percentage of cells containing
>10 RAD51 foci at 0 and 8 h upon irradiation (IR). Data are reported as mean ± SD. (C) Western blot
analysis and relative quantification of RAD51 protein levels in nucleus/cytosol fractions of DU145
WT or F133V cells at 0 and 8 h upon irradiation (6 Gy). HDAC2 and β-tubulin were used as equal
protein loading controls for nuclear and cytosolic fractions, respectively. Relative protein expression
was calculated as nuclear/cytosolic ratio of normalized RAD51 levels.
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Based on the knowledge that SPOP mutation impairs HR, we next examined the formation of
nuclear RAD51 foci, a specific marker of HR, upon irradiation in WT and mutated cells. Interestingly,
and consistent with the presence of γH2AX foci, RAD51 foci were markedly increased at 8 h upon
irradiation in WT SPOP cells but not in F133V SPOP cells, indicating that the presence of SPOP mutation
negatively interferes with the HR repair pathway (Figure 4B). Accordingly, through the assessment of
the nuclear translocation of RAD51, which underlies its engagement in the HR machinery, we observed
that RAD51 protein enrichment in the nuclear fraction increases in WT SPOP cells upon irradiation
but not in F133V SPOP cells, further confirming that RAD51 translocation and the consequent HR
machinery activation is impaired in SPOP-mutated cells (Figure 4C).
Taken together, these findings indicate that the presence of SPOP mutation, while not affecting
the induction and recognition of radiation-induced DNA damage, remarkably impairs the induction
of the HR DNA damage repair pathway in PCa cells by interfering with the formation of RAD51
nuclear foci.
2.3. Knockdown of SPOP Enhances PCa Cell Response to Ionizing Radiation
Nearly all PCa-specific SPOP mutations, including Y87N, K129E and F133V, reside in proximity
of the substrate-binding cleft of its MATH domain, indicating a loss of function phenotype [2].
This evidence suggests that an altered expression of SPOP may compromise its function as well as
the presence of loss-of-function mutations [6]. To investigate whether the loss of SPOP in PCa cells
produces a radiosensitizing effect comparable to that observed upon SPOP mutation, we performed
siRNA-based phenocopy experiments to specifically suppress endogenous SPOP in DU145 and PC-3
cells. Following siRNA-SPOP (siSPOP) transfection, SPOP transcript levels were significantly reduced
compared to negative control (siNeg) in both cell lines (Figure 5A). This reduction was paralleled by
a comparable decrease in the levels of SPOP protein, as shown by western blot analysis (Figure 5B),
thus confirming the ability of siSPOP to efficiently suppress the transcription and expression of
endogenous SPOP.
SPOP knockdown significantly inhibited DU145 and PC-3 cell proliferation over time up to
48% and 40%, respectively, compared to controls (Figure 5C) and reduced their plating efficiency
in the clonogenic assay (0.13 and 0.16 in siSPOP transfected DU145 and PC-3 cells, respectively,
compared to 0.22 and 0.28 of the corresponding siNeg cells). Interestingly, SPOP knockdown was
also able to significantly enhance cell response to radiation in both cell lines, similarly to what was
observed with SPOP mutants, suggesting that, although moderate, the slight knockdown of SPOP
is sufficient to exert a significant biological effect. Specifically, the DER values were 1.42 and 1.32 in
siSPOP-transfected DU145 and PC-3 cells, respectively, which are almost superimposable to that of
SPOP mutants, indicating that the loss of SPOP indeed recapitulated the radiosensitizing effect induced
by SPOP mutation (Figure 5D).
In addition, to explore the possibility of enhancing the radiation response suppressing SPOP
through the use of a physiological negative regulator of the gene, we focused on miR-145-5p,
which recently emerged as an upstream regulator of SPOP [20] and was also shown to increase
the radiosensitivity of PCa models by modulating DNA repair [21]. To this purpose, DU145 cells
were transfected with a synthetic miR-145 mimic, resulting in a significant downregulation of SPOP
at both transcript and protein levels, although lower than that observed with siSPOP (Figure 5E,F).
This evidence is in line with the miRNA characteristic of being fine tuners of gene expression. Moreover,
consistent with its negative modulation of SPOP expression, miR-145 showed an inhibitory effect on
cell proliferation and plating efficiency (0.17 in miR-145 transfected cells compared to 0.22 of Neg cells),
although at a lower extent compared to what was observed upon siSPOP transfection (Figure 5G).
Interestingly, miR-145 was able to remarkably increase DU145 sensitivity to radiation, as shown by
the decreased cell surviving fractions and corroborated by the DER value of 1.49, which is even slightly
greater than that observed upon siSPOP transfection (Figure 5H).
Cancers 2020, 12, 1462 8 of 15
Figure 5. SPOP knockdown, through siRNA-SPOP (siSPOP) or miR-145 transfection, enhances cell
response to radiation. (A) qRT-PCR detection of SPOP transcript levels in DU145 (upper panel) or PC-3
(lower panel) at 48 h upon transfection with siSPOP, compared to control cells, normalized to GAPDH.
Data are reported as relative quantity (RQ) ± SD with respect to siNeg transfectants. (B) Western
blot analysis and relative quantification of SPOP protein levels in DU145 and PC-3 cells at 48 h upon
siSPOP transfection. Vinculin was used as endogenous control. (C) Cell proliferation curves of siNeg
and siSPOP at 24, 48, 72 and 96 h upon transfection. Data are indicated as number of cells ×103 and are
reported as mean ± SD values (n = 3). (D) Clonogenic cell survival of DU145 and PC-3 cells upon
transfection with siNeg or siSPOP. The surviving fractions are reported as mean ± SD values from
three independent experiments. The dose enhancement ratio (DER) was calculated as the dose (Gy) for
the radiation plus siSPOP divided by the dose (Gy) for radiation plus siNeg at a surviving fraction
of 0.1. (E) qRT-PCR detection of SPOP transcript levels in DU145 cells at 48 h upon transfection with
miR-145, compared to control cells, normalized to GAPDH. Data are reported as relative quantity
(RQ) ± SD with respect to Neg cells. (F) Western blot analysis and relative quantification of SPOP
protein levels in DU145 cells at 48 h upon miR-145 transfection. Vinculin was used as control. (G) Cell
proliferation curves of Neg and miR-145 at 24, 48, 72 and 96 h upon transfection. Data are indicated
as number of cells ×103 and are reported as mean ± SD values from three independent experiments.
(H) Clonogenic cell survival of Neg or miR-145-transfected DU145 cells. The surviving fractions are
reported as mean ± SD values from three independent experiments. The dose enhancement ratio (DER)
was calculated as described above. The level of significance was represented as * p < 0.05, ** p < 0.01,
*** p < 0.001, Student’s t-test.
Collectively, these results substantiate our hypothesis that SPOP suppression, through the use
of either siRNA or miRNA molecules, recapitulates SPOP mutation potential in influencing PCa cell
response to radiation.
2.4. SPOP Knockdown Impairs Homologous Recombination via RAD51 and CHK1 Downregulation
To gain further insight into the mechanisms underlying the observed HR impairment in SPOP
deficient cells, and based on previous evidence that SPOP interferes with the transcription of main HR
mediators [14], we assessed the effect of SPOP knockdown on the expression of RAD51 and CHK1 in
the two PCa cell models. siRNA-mediated SPOP suppression significantly decreased the expression
of RAD51 and CHK1 mRNAs in DU145 and PC-3 cell lines, confirming that both factors of the HR
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machinery are regulated by SPOP at the transcriptional level (Figure 6A). Accordingly, the protein levels
of the two mediators were considerably reduced upon SPOP downregulation, suggesting that the loss
of SPOP function impairs HR-mediated DNA DSB repair through RAD51 and CHK1 downregulation
(Figure 6B). Consistent with these findings, when the formation of RAD51 foci following irradiation
was assessed in the presence or absence of SPOP knockdown, we found that RAD51 foci rapidly
accumulate and persist in siNeg cells, whereas their formation was significantly reduced in siSPOP
transfected cells (Figure 6C).
 
2 
 Figure 6. SPOP knockdown impairs HR via RAD51 and CHK1 downregulation. (A) qRT-PCR detection
of RAD51 and CHEK1 transcript levels in DU145 (upper panel) or PC-3 (lower panel) cells at 48 h upon
siSPOP transfection, compared to controls, normalized to GAPDH. Data are reported as relative quantity
(RQ) ± SD with respect to siNeg transfectants. (B) Western blot analysis and relative quantification of
RAD51 and CHK1 protein levels in DU145 and PC-3 cells at 48 h upon siSPOP transfection. Vinculin
was used as equal protein loading control. (C) Representative immunofluorescence microphotographs
of nuclear RAD51 foci (cell nuclei: blue; RAD51 foci: green) in DU145 (upper panel) or PC-3 (lower
panel) cells at 48 h upon transfection with siSPOP at 0, 0.5 and 6 h after exposure to 6 Gy irradiation
and relative quantification, expressed as mean percentage of cells containing >10 RAD51 foci at 0,
0.5 and 6 h after exposure to 6 Gy irradiation. Data are reported as mean ± SD values from three
independent experiments. The level of significance was represented as ** p < 0.01, *** p < 0.001,
Student’s t-test.
These results indicate that SPOP suppression leads to the downregulation of RAD51 and CHK1
and, consequently, to the impairment of the HR mechanism of DNA damage repair, hence entailing an
inadequate resolution of radiation-induced DNA DSBs.
3. Discussion
This is the first comprehensive study aimed at comparatively assessing the potential of deregulated
SPOP, via gene mutation or siRNA- and miRNA-mediated knockdown, as a radiosensitizing factor in
PCa experimental models. Specifically, we found that DU145 and PC-3 cells ectopically expressing a
PCa-associated SPOP mutation affecting the MATH domain (Y87N, K129E or F133V) were characterized
by markedly enhanced in vitro radiosensitivity profiles, as indicated by the significantly decreased
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clonogenic cell survival observed at all the tested doses. In addition, an original finding emerging
from the study is that all the assessed SPOP mutations showed a comparable radiosensitizing effect
in the context of a specific cell line. Most importantly, we demonstrated for the first time that stable
expression of F133V SPOP, which represents the SPOP mutation most frequently observed in clinical
PCa [2], was able to improve the in vivo response to 5 Gy irradiation in PCa mouse xenografts.
Phenocopy experiments carried out to assess the radiation response of DU145 cells upon SPOP
silencing with a specific siRNA showed that gene knockdown was able to induce a radiosensitizing
effect comparable to that observed in the presence of mutant SPOP. Superimposable results were also
obtained through the ectopic expression of miR-145-5p, which recently emerged as a physiological
negative regulator of SPOP from a pathway analysis in prostate organoids from conditional SPOP-F133V
transgenic mouse [13]. Indeed, the 3′-UTR regions of both mouse and human SPOP transcripts harbor
a conserved putative miR-145 binding site [20]. Consistent with our findings, miR-145 reconstitution
was previously shown to increase the radiosensitivity of PCa models [21].
Taken together, the data support the notion that SPOP downregulation, as accomplished by either
gene mutation or RNAi-mediated knockdown, is consistently able to improve the radiation response
of PCa models.
In accordance with the previously reported involvement of SPOP in determining cell response
to radiation by influencing DNA damage repair [15,16], the comparative transcriptomic analysis
performed in DU145 cells carrying WT or F133V SPOP to assess relevant pathways differentially
expressed showed that the “DNA repair” gene set, which comprises all the pathways related to
DNA repair mechanisms, was downregulated upon SPOP mutation. Consistently, the functional
characterization of the effect of mutant SPOP in radiation-induced DNA damage and repair through
the assessment of the kinetics of accumulation and removal of γH2AX foci, as a specific marker of
the presence of DNA DSBs, indicated that, although treatment induced an extensive and comparable
amount of DNA lesions in WT and F133V SPOP cells, the resolution of γH2AX foci was markedly
delayed in mutant SPOP expressing cells. Consistent with a different presence of γH2AX foci,
an increased nuclear translocation of RAD51 protein, which underlies its engagement in the HR
machinery, together with a markedly enhanced presence of RAD51 foci upon irradiation was observed
in WT SPOP cells but not in F133V SPOP cells, thus corroborating previous evidence indicating that
SPOP mutation negatively interferes with the HR repair pathway [7]. Superimposable results were
obtained in DU145 and PC-3 cells upon RNAi-mediated SPOP knockdown. Moreover, in accordance
with recently reported findings showing that SPOP promotes the transcriptional expression of DNA
repair factors including RAD51 and CHK1 and that SPOP knockdown impairs RAD51 foci formation
and CHK1 activation at the transcriptional level in response to replication stress [14], we found
that the expression of the two genes was markedly reduced at both RNA and protein levels in
siSPOP-transfected PCa cells.
Overall, these findings indicate that the presence of mutant or downregulated SPOP, while not
affecting the induction and recognition of radiation-induced DNA damage, significantly impairs
the HR repair pathway in PCa cells by interfering with the formation of RAD51 nuclear foci in response
to DNA DSB induction. In addition, results from the study corroborate the notion that mutant SPOP
could represent a novel biomarker of radiation sensitivity and also highlight the possibility to develop
novel strategies of radiosensitization based on the use of SPOP downregulation approaches.
4. Materials and Methods
4.1. Experimental Models
The human DU145 and PC-3 PCa cell lines (American Type Culture Collection, ATCC, Manassas,
VA, USA) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS).
Cell lines were authenticated and monitored via genetic profiling using short tandem repeat analysis
(AmpFISTR Identifiler PCR amplification kit, Thermo Fisher Scientific Inc., Waltham, MA, USA).
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4.2. Cell Transfection
For the ectopic expression of WT and mutant SPOP, cells were seeded at the density of 8000 cells/cm2
in culture vessels and transfected with 50 µg pMCV6-Entry vectors expressing WT or mutant (Y87N,
F102C, F133V) SPOP protein tagged with a C-terminal Myc/FLAG epitope (kindly provided by Drs.
M.A. Rubin and C. Barbieri [2]), using Lipofectamine 2000 (Thermo Fisher Scientific Inc.). For in vivo
experiments, DU145 clones stably expressing WT SPOP and F133V SPOP were established. Cells were
transfected according to Lipofectamine 3000 protocol (Thermo Fisher Scientific Inc.). Briefly, cells were
seeded in 6-well plates (5 × 105 cells/well) and 24 h later transfected with vectors (10 pg). After 72 h,
cells were selected using 0.4 mg/mL zeocin for 5 weeks. Stable transfectants were stored in liquid
nitrogen at −196 ◦C. When cultured, transfected cells were maintained in the presence of 0.2 mg/mL
of zeocin.
To downregulate endogenous SPOP expression, cells were transfected for 4 h with 20 nM
mirVana miRNA mimic (miR-145 MC11480, Thermo Fisher Scientific Inc., Waltham, MA, USA)
and mirVana miRNA mimic Negative control (miR-Neg Negative control #1, Thermo Fisher Scientific
Inc.) using Lipofectamine RNAiMAX (Thermo Fisher Scientific Inc.), or with 20 nM Silencer Select
Pre-Designed siRNA-SPOP (siSPOP, Silencer Select Pre-Designed siRNA-SPOP_s15955, Thermo Fisher
Inc.) and Silencer Select Negative Control (siNeg) using Lipofectamine 2000 (Thermo Fisher Scientific
Inc.), according to the manufacturer’s instructions. Specifically, miR-145-based experiments were
carried out on DU145 since we already have a lot of experience in reconstituting different miRNAs in
this cell line [22,23] and have already obtained reproducible results.
4.3. Cell Proliferation
Cells were seeded in 6-well plates at the density of 4000 cells/cm2 and transfected with miRNA
mimics or siRNAs 24 h later. Cells were detached and counted through a Coulter Counter (Beckman
Coulter Life Sciences, Brea, CA, USA) at different time points (24, 48, 72 and 96 h). Data were reported
as number of proliferative cells ×103.
4.4. Clonogenic Assay
Transfected cells were irradiated with increasing doses (2–8 Gy) delivered as a single dose using
the 137Cs γ-irradiator IBL-437 (dose rate 5.2 Gy/min). Specifically, cell samples were placed in
the central region of the irradiation cavity where the dose uniformity is ensured with a tolerance of 5%.
The time of irradiation takes into account the correction for radioisotopic decay, which is monitored
every 6 months. Irradiated cells were seeded in triplicate at increasing densities (500–8000 cells/well),
in 6-well plates cultured in RPMI complete medium. After 10 and 14 days, DU145 and PC-3 colonies,
respectively, were fixed with 70% ethanol, stained with crystal violet in 70% ethanol, and counted
(only colonies consisting of at least 50 cells were considered). The plating efficiency was calculated
as the ratio of the number of colonies to the number of seeded cells. The surviving fraction was
calculated as the ratio of the plating efficiency of the irradiated cells to that of the non-irradiated ones.
The dose enhancement ratio (DER) was calculated as the ratio of the radiation dose required to obtain
a surviving fraction of 0.1 in control cells to that required to obtain the same SF in mutant/silenced
SPOP cells. GraphPad Prism was used to fit the linear-quadratic model of cell clonogenic survival
based on the equation Y = exp (−1 × (A × X + B × X2)), which has been established to be a suitable
model for the description of cell death upon irradiation [24].
4.5. In Vivo Experiments
All animal experiments were approved by the Ethics Committee for Animal Experimentation of
Fondazione IRCCS Istituto Nazionale dei Tumori and by the Italian Health Ministry (#1120/2015PR).
For the generation of xenografts, DU145 cell line was used since it is characterized by an efficient
engraftment in mice. Ten million DU145 cells transfected with WT and F133V SPOP vectors were
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injected into the right flank of eight-week-old male SCID mice. When tumors reached ~300 mm3
(Width2 × Length/2), mice were randomly assigned to mock or radiation treatment groups (n = 8).
Using a micro-CT/microirradiator (225Cx, Precision X-ray) mice were exposed to 5 Gy single dose
irradiation, a dose that emerged as the best compromise between efficacy and safety, based on our
previous experience [22,23] and literature data [25,26].
Specifically, mice were anesthetized with a solution of ketamine (100 mg/kg) + xylazine (5 mg/kg)
and imaged through cone-beam computer tomography (CBCT) using a micro-CT/microirradiator
(225Cx, Precision X-ray) with filtration of 2 mm of aluminum. The resulting imaging scan was used for
the delineation of tumor contouring using SmART Plan software.
For mice treatment, two parallel opposed fields were created to cover the target with the prescribed
dose, delivering irradiation through 0.3 mm of copper filtration and a square collimator (1 × 1 cm).
After the Monte Carlo-based dose calculation, the dose-volume histogram (DVH) was checked to
ensure that 100% of the target received 100% of the prescribed dose (the gross tumor volume was
contoured). Sparing of animal body and other organs were ensured by using tangential radiation
beams. Finally, to expose all mice to the same conditions, radiotherapy was delivered in a single
fraction of 0 Gy and 5 Gy for the control group and the treatment group, respectively. To determine
tumor growth, a Vernier caliper was used to regularly measure tumor size.
4.6. Total RNA Extraction and RT-qPCR
RNA extraction and cDNA synthesis were performed to assess miRNA and gene expression
levels. RNA was isolated using QIAzol Lysis Reagent and a miRNeasy Mini Kit (QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions. cDNA was synthesized using a miScript II RT
Kit (Thermo Fisher Scientific Inc.).
Quantification of gene or miRNA expression was assessed using RT-qPCR with the following
TaqMan microRNA or gene expression assays (Thermo Fisher Scientific Inc.): SPOP (Hs00737433_m1),
RAD51 (Hs00947967_m1) and CHEK1 (Hs00967506_m1).
For comparative analyses, GAPDH (TaqMan Gene Expression Assay, Hs02786624_g1) and SNORD
(TaqMan non coding RNA assay, Hs04931161_g1) were used as endogenous controls for genes
and miRNA, respectively. RT-qPCR results were reported as relative quantity (RQ = 2-ddCt) with
respect to a calibrator sample using the comparative Ct (ddCt) method.
4.7. Immunoblotting Analyses
Cell lysates (20 µg) were fractioned using SDS-PAGE and transferred onto nitrocellulose
membranes using standard protocols. Membranes were blocked in PBS-Tween-20/0.5% skim milk
and probed overnight with the following antibodies: RAD51 (MA5-14419, Invitrogen, Carlsbad,
California, USA), gamma H2AX (phospho S139) (ab11174, Abcam, Cambridge, UK), H2AX (ab11175,
Abcam), SPOP (ab137537, Abcam), CHK1 (ab47444, Abcam). GAPDH (G8795, Sigma-Aldrich, St. Louis,
Missouri, USA), β–tubulin (T521, Sigma-Aldrich), Vinculin (V9131, Sigma-Aldrich) and HDAC
(877-616-cell, Cell Signaling, Danvers, MA, USA) were used as equal protein loading controls.
Detection of bound peroxidase linked secondary antibodies was assessed using a Novex ECL,
HRP Chemiluminescent Substrate Reagent Kit (Thermo Fisher Scientific Inc.). Original whole blots
were cropped to generate figure panels showing relevant proteins. Cropped images were subjected to
uniform image enhancement of contrast and brightness. Molecular weights were determined using
the colorimetric Precision Plus Protein Standard (Bio-Rad, Hercules, CA, USA). Whole blots showing
all the bands with molecular weight markers were provided in Figure S1.
4.8. Immunofluorescence
Transfected cells grown on SlideFlasks (Nunc Lab-Tek Flask on Slide, 17092, Thermo Fisher
Scientific Inc.) were fixed with 4% formaldehyde and permeabilized with cold methanol:acetone,
1:1 solution. Cells were probed with primary antibodies for phospho-Histone H2AX (ab11174, Abcam),
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RAD51 (MA5-14419, Invitrogen) and subsequently with Alexa Fluor488-labeled (Thermo Fisher
Scientific Inc.) secondary antibodies for 1 h at room temperature. Based on clonogenic cell survival
results, we chose 6 Gy as an informative dose to assess phospho-H2AX foci. Nuclei were counterstained
with DAPI (Thermo Fisher Scientific Inc.). Images were acquired using a Nikon Eclipse E600 microscope
with ACT-1 software (Nikon, New York, NY, USA). At least ten single-layer fluorescence images
were taken per condition, in triplicate, and a total of >300 cells/condition were manually counted.
Based on a conventional threshold reported in literature [27,28], only cells containing >10 foci were
considered positive.
4.9. Bioinformatic Analyses
Transcriptomic data from DU145 prostate cells ectopically expressing WT SPOP (three independent
samples) and F133V mutant SPOP (three independent samples) was generated in our laboratory
using Illumina HumanHT-12 v4 arrays. The genomic alteration and the wild-type control cells were
conducted in triplicate for bioinformatics analysis. Raw data were log2-transformed and normalized
using the robust spline method implemented in the lumi package [29]. Normalized data were filtered
removing probes with neither at least one detection p-value < 0.01 across samples nor an associated
official gene symbol; for probes mapping on the same gene symbol, the one with highest variance
was selected.
Gene expression data was deposited at Gene Expression Omnibus, with accession number
GSE147090. Differential expression was estimated in terms of t-value, using the limma Bioconductor
package [30]. Significance was provided in terms of a false-discovery rate (FDR) to take into account
the adjustment for multiple hypotheses testing. A t-value preranked gene set enrichment analysis
(GSEA v4.0.3) [31] was performed using Hallmark gene sets and GO biological process collection v7 of
the Molecular Signature database (MSigDB) [32]. An FDR q-value threshold of 0.05 was used to assess
a significant enrichment.
All these analyses were conducted in R environment.
4.10. Statistical Analyses
Data are shown as mean values ± SD from at least three independent experiments. Statistical
analysis was performed using two-tailed Student’s t test. p-values < 0.05 were considered
statistically significant.
5. Conclusions
In the precision medicine era, a reliable definition of the role of mutant SPOP as a radiosensitizing
factor could contribute to tailoring therapy of individual PCa patients by delivering a genomic-adjusted
radiation dose, instead of a uniform dose (i.e., one-size-fits-all). In addition, the possibility to enhance
the radiation response through siRNA/miRNA-mediated SPOP downregulation will open an avenue
for the design of radiosensitizing approaches through the targeting of gene negative regulators.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/6/1462/s1,
Table S1: Plating efficiency values of DU145 and PC-3 cells transfected with WT or mutant SPOP; Figure S1:
Whole blots showing all the bands with molecular weight markers.
Author Contributions: Conceptualization, N.Z.; data curation, R.E.B., S.P. and A.C.; formal analysis, R.E.B., S.P.
and N.Z.; funding acquisition, N.Z.; investigation, R.E.B., M.T. (Martina Tripari), S.P., M.T. (Monica Tortoreto),
C.S., S.T., V.Z., V.D. and P.G.; methodology, R.E.B.; resources, N.Z.; software, A.C.; supervision, R.V. and N.Z.;
visualization, R.E.B.; writing—original draft, R.E.B., S.P. and N.Z.; writing—review and editing, R.E.B., S.P., A.C.
and N.Z. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by grants from AIRC (15191) and the I. Monzino Foundation.
Acknowledgments: The authors would like to thank Mark A. Rubin, University of Bern, and Christopher E. Barbieri,
Cornell University, New York, for providing WT and mutant SPOP expressing vectors, and Marzia Pennati
and Giovanni Beretta for providing their technical contribution.
Cancers 2020, 12, 1462 14 of 15
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Zhuang, M.; Calabrese, M.F.; Liu, J.; Waddell, M.B.; Nourse, A.; Hammel, M.; Miller, D.J.; Walden, H.;
Duda, D.M.; Seyedin, S.N.; et al. Structures of SPOP-Substrate Complexes: Insights into Molecular
Architectures of BTB-Cul3 Ubiquitin Ligases. Mol. Cell 2009, 36, 39–50. [CrossRef] [PubMed]
2. Barbieri, C.E.; Baca, S.C.; Lawrence, M.S.; Demichelis, F.; Blattner, M.; Theurillat, J.P.; White, T.A.; Stojanov, P.;
Van Allen, E.; Stransky, N.; et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations
in prostate cancer. Nat. Genet. 2012, 44, 685–689. [CrossRef]
3. Le Gallo, M.; O’Hara, A.J.; Rudd, M.L.; Urick, M.E.; Hansen, N.F.; O’Neil, N.J.; Price, J.C.; Zhang, S.;
England, B.M.; Godwin, A.K.; et al. Exome sequencing of serous endometrial tumors identifies recurrent
somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat. Genet. 2012, 44, 1310.
[CrossRef] [PubMed]
4. Li, G.; Ci, W.; Karmakar, S.; Chen, K.; Dhar, R.; Fan, Z.; Guo, Z.; Zhang, J.; Ke, Y.; Wang, L.; et al. SPOP
promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 2014, 25, 455–468.
[CrossRef] [PubMed]
5. Baca, S.C.; Prandi, D.; Lawrence, M.S.; Mosquera, J.M.; Romanel, A.; Drier, Y.; Park, K.; Kitabayashi, N.;
MacDonald, T.Y.; Ghandi, M.; et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153, 666–677.
[CrossRef] [PubMed]
6. Boysen, G.; Barbieri, C.E.; Prandi, D.; Blattner, M.; Chae, S.S.; Dahija, A.; Nataraj, S.; Huang, D.; Marotz, C.;
Xu, L.; et al. SPOP mutation leads to genomic instability in prostate cancer. eLife 2015, 4, e09207. [CrossRef]
7. Abeshouse, A.; Ahn, J.; Akbani, R.; Ally, A.; Amin, S.; Andry, C.D.; Annala, M.; Aprikian, A.; Armenia, J.;
Arora, A.; et al. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015, 163, 1011–1025. [CrossRef]
8. Theurillat, J.P.P.; Udeshi, N.D.; Errington, W.J.; Svinkina, T.; Baca, S.C.; Pop, M.; Wild, P.J.; Blattner, M.;
Groner, A.C.; Rubin, M.A.; et al. Ubiquitylome analysis identifies dysregulation of effector substrates in
SPOP-mutant prostate cancer. Science 2014, 346, 85–89. [CrossRef]
9. Geng, C.; Rajapakshe, K.; Shah, S.S.; Shou, J.; Eedunuri, V.K.; Foley, C.; Fiskus, W.; Rajendran, M.; Chew, S.A.;
Zimmermann, M.; et al. Androgen receptoristhe keytranscriptional mediatorofthe tumor suppressor SPOP
in prostate cancer. Cancer Res. 2014, 74, 5631–5643. [CrossRef]
10. An, J.; Wang, C.; Deng, Y.; Yu, L.; Huang, H. Destruction of Full-Length Androgen Receptor by Wild-Type
SPOP, but Not Prostate-Cancer-Associated Mutants. Cell Rep. 2014, 6, 657–669. [CrossRef]
11. Geng, C.; He, B.; Xu, L.; Barbieri, C.E.; Eedunuri, V.K.; Chew, S.A.; Zimmermann, M.; Bond, R.; Shou, J.; Li, C.;
et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor
coactivator 3 protein turnover. Proc. Natl. Acad. Sci. USA 2013, 110, 6997–7002. [CrossRef] [PubMed]
12. Groner, A.C.; Cato, L.; de Tribolet-Hardy, J.; Bernasocchi, T.; Janouskova, H.; Melchers, D.; Houtman, R.;
Cato, A.C.B.; Tschopp, P.; Gu, L.; et al. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
Cancer Cell 2016, 29, 846–858. [CrossRef] [PubMed]
13. Blattner, M.; Liu, D.; Robinson, B.D.; Huang, D.; Poliakov, A.; Gao, D.; Nataraj, S.; Deonarine, L.D.;
Augello, M.A.; Sailer, V.; et al. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate
Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 2017, 31, 436–451. [CrossRef]
14. Hjorth-Jensen, K.; Maya-Mendoza, A.; Dalgaard, N.; Sigurðsson, J.O.; Bartek, J.; Iglesias-Gato, D.; Olsen, J.V.;
Flores-Morales, A. SPOP promotes transcriptional expression of DNA repair and replication factors to
prevent replication stress and genomic instability. Nucleic Acids Res. 2018, 46, 9484–9495. [CrossRef]
15. Zhang, D.; Wang, H.; Sun, M.; Yang, J.; Zhang, W.; Han, S.; Xu, B. Speckle-type POZ protein, SPOP, is involved
in the DNA damage response. Carcinogenesis 2014, 35, 1691–1697. [CrossRef] [PubMed]
16. Dong, Y.; Zhang, D.; Cai, M.; Luo, Z.; Zhu, Y.; Gong, L.; Lei, Y.; Tan, X.; Zhu, Q.; Han, S. SPOP regulates
the DNA damage response and lung adenocarcinoma cell response to radiation. Am. J. Cancer Res. 2019, 9,
1469.
17. Mottet, N.; Bellmunt, J.; Bolla, M.; Briers, E.; Cumberbatch, M.G.; De Santis, M.; Fossati, N.; Gross, T.;
Henry, A.M.; Joniau, S.; et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis,
and Local Treatment with Curative Intent. Eur. Urol. 2017, 71, 618–629. [CrossRef]
Cancers 2020, 12, 1462 15 of 15
18. Tetreault-Laflamme, A.; Crook, J. Options for Salvage of Radiation Failures for Prostate Cancer. Semin. Radiat.
Oncol. 2017, 27, 67–78. [CrossRef]
19. Chang, L.; Graham, P.H.; Hao, J.; Bucci, J.; Cozzi, P.J.; Kearsley, J.H.; Li, Y. Emerging roles of radioresistance
in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev. 2014, 33, 469–496. [CrossRef]
20. Huang, C.J.; Chen, H.Y.; Lin, W.Y.; Choo, K.B. Differential expression of speckled POZ protein, SPOP: Putative
regulation by miR-145. J. Biosci. 2014, 39, 401–413. [CrossRef]
21. Gong, P.; Zhang, T.; He, D.; Hsieh, J.-T. MicroRNA-145 Modulates Tumor Sensitivity to Radiation in Prostate
Cancer. Radiat. Res. 2015, 184, 630–638. [CrossRef] [PubMed]
22. El Bezawy, R.; Cominetti, D.; Fenderico, N.; Zuco, V.; Beretta, G.L.; Dugo, M.; Arrighetti, N.; Stucchi, C.;
Rancati, T.; Valdagni, R.; et al. miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances
radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. Cancer Lett. 2017, 395,
53–62. [CrossRef] [PubMed]
23. El Bezawy, R.; Tinelli, S.; Tortoreto, M.; Doldi, V.; Zuco, V.; Folini, M.; Stucchi, C.; Rancati, T.; Valdagni, R.;
Gandellini, P.; et al. miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA
damage repair through PKCε and ZEB1 inhibition. J. Exp. Clin. Cancer Res. 2019, 38, 51. [CrossRef] [PubMed]
24. Bodgi, L.; Canet, A.; Pujo-Menjouet, L.; Lesne, A.; Victor, J.M.; Foray, N. Mathematical models of radiation
action on living cells: From the target theory to the modern approaches. A historical and critical review.
J. Theor. Biol. 2016, 394, 93–101. [CrossRef]
25. Citrin, D.E.; Shankavaram, U.; Horton, J.A.; Shield, W.; Zhao, S.; Asano, H.; White, A.; Sowers, A.; Thetford, A.;
Chung, E.J. Role of type II pneumocyte senescence in radiation-induced lung fibrosis. J. Natl. Cancer Inst.
2013, 105, 1474–1484. [CrossRef]
26. Seol, M.A.; Jung, U.; Eom, H.S.; Kim, S.H.; Park, H.R.; Jo, S.K. Prolonged expression of senescence markers in
mice exposed to gamma-irradiation. J. Vet. Sci. 2012, 13, 331–338. [CrossRef]
27. Hatano, K.; Kumar, B.; Zhang, Y.; Coulter, J.B.; Hedayati, M.; Mears, B.; Ni, X.; Kudrolli, T.A.; Chowdhury, W.H.;
Rodriguez, R.; et al. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate
cancer cells to ionizing radiation. Nucleic Acids Res. 2015, 43, 4075–4086. [CrossRef]
28. Chiu, Y.T.; Liu, J.; Tang, K.; Wong, Y.C.; Khanna, K.K.; Ling, M.T. Inactivation of ATM/ATR DNA damage
checkpoint promotes androgen induced chromosomal instability in prostate epithelial cells. PLoS ONE 2012,
7, e51108. [CrossRef]
29. Du, P.; Kibbe, W.A.; Lin, S.M. lumi: A pipeline for processing Illumina microarray. Bioinformatics 2008.
[CrossRef]
30. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. Limma powers differential
expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43, e47. [CrossRef]
31. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.; Gillette, M.A.; Paulovich, A.;
Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach
for interpreting genome-wide. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [CrossRef] [PubMed]
32. Shannon, P.; Markiel, A.; Ozier, O.S.; Baliga, N.T.; Wang, J.; Ramage, D.; Amin, N.; Schwikowski, B.;
Ideker, T. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks.
Genome Res. 2003, 13, 2498–2504. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
